OSE Immunotherapeutics has been granted a patent for humanized monoclonal antibodies targeting CD127, the alpha chain of the IL7 receptor. The patent covers therapeutic and diagnostic applications, including inhibiting inflammation associated with the IL-7 signaling pathway by administering anti-human CD127 agents. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights OSE Immunotherapeutics SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Humanized monoclonal antibodies targeting cd127 for therapeutic and diagnostic use

Source: United States Patent and Trademark Office (USPTO). Credit: OSE Immunotherapeutics SA

A recently granted patent (Publication Number: US11926671B2) discloses a method for inhibiting inflammation associated with the interleukin-7 (IL-7) signaling pathway by administering a composition containing an anti-human CD127 agent to a patient in need. The anti-human CD127 agent includes an antibody or antigen-binding fragment that specifically binds to CD127, targeting diseases such as autoimmune diseases, allergic diseases, cancer, respiratory diseases, and chronic viral infections linked to IL-7 signaling.

The method outlined in the patent involves the use of a humanized monoclonal antibody as the anti-human CD127 agent, with specific sequences identified for the antibody light chain and heavy chain variable domains. The antibody acts as an antagonist of IL-7 receptor signaling induced by IL-7, disrupting the binding of CD127 to the ?c common chain of cytokine receptors. Additionally, the antibody does not induce the activation of certain signaling pathways, internalization of CD127, or increase dendritic cell maturation induced by Thymic Stromal Lymphopoietin (TSLP). The patent also highlights the long-lasting and fast effects of the antibody on the immune response post-administration, emphasizing its potential therapeutic value in managing inflammation associated with various diseases.

To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies